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We conducted a meta-analysis using results from the
Korean literature to determine whether prostate-specific anti-
gen (PSA) or digital rectal examination (DRE) or transrectal
ultrasonography (TRUS) provides a better diagnostic outcome
for possible prostate cancer patients. An extensive literature
search of MedRIC database et al. (1980 to 2003) was per-
formed using the medical subject headings "PSA", "DRE",
"TRUS" and "prostate cancer". Of the 108 articles that we
retrieved, 13 studies (2,029 subjects) were selected for this
meta-analysis. The criteria for quality evaluation were as fol-
lows: the study subjects must have been compared clinically
for suspected prostate cancer, and the articles must have
included individual data about sensitivity and specificity for
this diagnostic triad based on the biopsy results as a reference
standard. For the quantitative meta-analysis process the
Hasselblad method was utilized. The pooled sensitivity and
specificity for a PSA level greater than 4 ng/mL were 91.3%
and 35.9%, respectively; and those for a PSA level greater
than 10 ng/mL were 77.3% and 67.5%, respectively; and those
for DRE were 68.4% and 71.5%, respectively; and those for
TRUS were 73.6% and 61.3%, respectively. According to the
results in a fixed effect model for PSA criteria, the estimates
of d ̅for PSA4 and PSA10 were 0.8517 [95% confidence
interval (CI): 0.6694, 1.0340] and 1.0996 (95% CI: 0.9459,
1.2534), respectively. Also, according to the results using a
random effect model for both DRE and TRUS criteria, the
estimates of d ̅for DRE and TRUS were 0.8398 (95% CI:
0.7169, 0.9627) and 0.8002 (95% CI: 0.6714, 0.9289), respec-
tively. The detection rate for combination testing of PSA, DRE
and TRUS for the diagnosis of prostate cancer jumped further
to 68.3% or to 76.8%. In conclusion, this study suggests that
this diagnostic triad for prostate cancer was noneffective when
they were used separately. Therefore, we recommend that the
urologists should use PSA together with DRE and TRUS for
the primary diagnosis of prostate cancer in men with lower
urological symptoms.
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INTRODUCTION
Prostate cancer among adult males is the most
common neoplasm after skin cancer in most
developed countries. Over 200,000 men in the
United States are diagnosed annually with pros-
tate cancer and 30,000 men still die from this dis-
ease each year.
1 The age-standardized incidence of
prostate cancer in the European Union is 65/
100,000 and the EU's mortality rate is 26/100,000
per year.
2 In South Korea the incidence rate of this
disease increased from 0.41 per 100,000 during
1985-1989 to 3.38 per 100,000 during 1995-1999.
The crude incidence rate of prostate cancer among
Korean men estimated to be 10.09 per 100,000.
After 50 years old, the age-specific incidence rate
increases three or four-fold for every 10-year
increase in age.
3 These trends have been shown to
be related to diet (i.e. the high consumption of
meat, dairy products and fats) by Whittemore et
al.
4 and Kolonel et al.,
5 and also to the improved
diagnostic techniques
6,7 [including prostate-spe-
Prostate-Specific Antigen, Digital Rectal Examination and
Transrectal Ultrasonography: A Meta-Analysis for This
Diagnostic Triad of Prostate Cancer in Symptomatic Korean
Men
Jae Mann Song
1, Chun-Bae Kim
2,3, Hyun Chul Chung
1, and Robert L. Kane
3
Departments of
1Urology and
2Preventive Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea;
3Clinical Outcomes Research Center, University of Minnesota School of Public Health, Minneapolis, USA.
Received May 20, 2004
Accepted December 21, 2004
This work was supported by a grant from the Korean Urological
Association (2003).
Reprint address: requests to Dr. Chun-Bae Kim, Department of
Preventive Medicine, Yonsei University Wonju College of Medi-
cine, Wonju 220-701, Korea. Tel: 82-33-741-0344, Fax: 82-33-747-
0409, E-mail: kimcb@wonju.yonsei.ac.krMeta-analysis of PSA, DRE and TRUS
Yonsei Med J Vol. 46, No. 3, 2005
cific antigen (PSA), transrectal ultrasonography
(TRUS), prostatic acid phosphatase, bone scan,
computed tomography, magnetic resonance im-
aging and etc]. Proteomics (surface-enhanced laser
desorption/ionization mass spectrometry
8) and
cDNA microarray analysis
9 have recently been
used as sensitive and specific diagnostic serum
and tissues tests for prostate cancer.
Among these diagnostic methods of prostate
cancer, the digital rectal examination (DRE) is the
oldest and least invasive test modality. Although
false negative and positive exams on DRE may
occur, DRE does detect some prostate cancers that
are missed by PSA screening. PSA (i.e., 33-kd
glycoprotein consisting of 240 amino acids) is a
serine protease that is secreted by the prostate
into the semen where it causes lysis of the seminal
coagulum. The determination of serum PSA has
become the most commonly used tumor marker
for prostate cancer
10 since the earliest investiga-
tion of tissue-specific antigens of the human
prostate by Ablin et al. in 1970
11 and the applica-
tion of an immunoassay method for PSA by Wang
et al. in 1979.
12 This diagnostic procedure was
introduced to Korea by Dr. Kang J. H. in the early
1980s.
13 After 1990, there has been an even more
dramatic surge in the incidence of prostate cancer
following the widespread adoption of serum PSA
testing. Moreover, since the introduction of a
clinical diagnostic method of prostatic diseases by
Watanabe et al. in 1971, the TRUS test has been
the diagnosis of choice for prostate cancer.
14 A
research result on this diagnostic test was pub-
lished in Korea by Dr. Kim N.D. in 1982.
15 There-
fore, urologists commonly perform clinical assess-
ment by using DRE and serum PSA for patients
presenting with urinary symptoms. Additionally,
radiological examinations including TRUS may
also be employed for assessing the size, form and
glandular structure of the prostate and any pos-
sible capsular or seminal vesicle involvement.
Numerous retrospective series have been per-
formed and published to date on this diagnostic
triad (PSA, DRE and TRUS). In addition, meta-
analyses have been conducted to evaluate the
effectiveness of this diagnostic triad or on two of
these methods that are related to prostate can-
cer.
16-22 Two of these studies have indicated that
if all three tests were abnormal, the risk of cancer
on meta-analysis was 68%,
18 and when an ex-
aminee has abnormal findings using PSA and
DRE, the chance of cancer was from 20-25%.
22
However, after 1990, various individual studies on
combined PSA, DRE and TRUS for the diagnosis
of prostate cancer also have been reported in
Korea, but no meta-analysis has been conducted.
Therefore, the aim of this study was to examine
the Korean literature with a focus on sensitivity
and specificity for comparing the major diagnostic
methods of prostate cancer, i.e., PSA, DRE and
TRUS, by employing quantitative meta-analysis,
and we wanted to determine the relative merits of
this diagnostic triad for symptomatic Korean men.
MATERIALS AND METHODS
Searching of data
The first step of our study involved searching
the medical journal database sites, i.e., the Medical
Research Information Center (MedRIC) (http:/ /
www.medric.or.kr/) and the National Assembly
Library of the Republic of Korea (http:/ /www.
nanet.go.kr/) from 1980 to 2003. In addition, we
searched other potential sources and gave priority
to the Korean Journal of Urology (http:/ /www.u
rology.or.kr/) and the Korean Journal of Androl-
ogy (http:/ /www.andrology.or.kr/). The second
step involved a manual search of the contents and
bibliographies of each of the retrieved studies.
This search was restricted to the Korean-lan-
guages studies that were conducted on men with
lower urinary symptoms. The medical subject
headings used for this search were prostate cancer
and diagnosis, prostate-specific antigen, digital
rectal examination and transrectal ultrasono-
graphy.
Meta-analysis
A total of 108 Korean articles were selected that
contained information on the comparative results
of using PSA, DRE and TRUS for the diagnosis of
prostate cancer. Two observers who were both
urologist and meta-analyst independently placed
the results of the individual articles onto a data
sheet; any disagreements were resolved by discus-Jae Mann Song, et al.
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sion. The inclusion criteria for this meta-analysis
were as follows. 1) Patients who had lower uri-
nary symptoms of prostate cancer or benign pros-
tate hyperplasia. These symptoms were mainly
disturbances of urination, hematuria, etc. 2) The
diagnostic PSA, DRE and TRUS tests for the
clinical diagnosis of prostate cancer must have
been simultaneously compared in the each article.
3) The studies included biopsy results as a refer-
ence standard to confirm prostate cancer. 4) The
articles must have contained sufficient or available
numeric information such as a 2 × 2 contingency
data table or the patients' outcome data, e.g., data
in terms of sensitivity (Sn), specificity (Sp), and
percent agreement of the PSA, DRE, and TRUS
testing. Of the 44 articles that were evaluated at
the final stage, only 13 of the studies that com-
pared PSA, DRE and TRUS met these inclusion
criteria, and so these were selected for the meta-
analysis.
For the quantitative meta-analysis process, the
Hasselblad method
23,24 was utilized with the SAS
system
TM by Song H.H.
25 To integrate results, the
sensitivity and specificity on each study's outcome
data were used as effect sizes, and the d ̅ value and
95% confidence interval (CI) of d ̅ were estimated.
Concerning the fixed effects model, additional
homogeneity tests were conducted.
Each the estimates of d ̅ , the variance of d ̅ , 95%
CI of d ̅ and homogeneity test were produced as
follows.
Estimate of
d : d= 3[loge(Sn/(1-Sn))+loge(Sp/(1-Sp))]/π
(Sn; sensitivity, Sp; specificity)
d= 3[loge(A+1/2)+loge(D+1/2)-loge(B+1/2)-
loge(C+1/2)]/ π
(A; true positive, B; false positive, C; false
negative, D; true negative in the 2×2 con-
tingency table)
Variance of d:
var(d) 3[1/(A+1/2)+1/(B+1/2)+1/(C+1/2)+
1/(D+1/2)]/π
2
The combining estimates of effectiveness (d ̅ ) in m
studies are usually given by the weighted mean:
d ̅ =(Σωjdj)/(Σωj), (j=1, 2, 3, ---, m)
where ωj=1/var (dj)
Variance of the combined estimate:
Var (d ̅ )=1/(Σωj)
95% CI for the average effect size: d ̅ ±1.96 Var (d ̅ )
Homogeneity test: Q=Σωj(dj-d ̅ )
2 ~ χ
2
(m-1)
RESULTS
The general characteristics of the 13 studies
26-38
are summarized in Table 1. All the studies were
published after 1991. A total of 2,029 men with
lower urinary symptoms had PSA and DRE
performed. Among those men, TRUS were per-
formed on 1,947 of them. All the subjects had
TRUS guided transurethral biopsy or transure-
thral prostatectomy
27,36 for the pathological diag-
nosis of prostate cancer. Of the 2,029 symptomatic
men, 516 of them (25.4%) were pathologically dia-
gnosed as having prostate cancer, with each study
having a wide range (13.5-41.5%). The others were
diagnosed with benign prostate hyperplasia
(72.9%) and chronic prostatitis etc. (1.7%). The
mean age of the patients was 67.8 years and the
age of these patients ranged from 30 to 93 years
old. The authors of all 13 studies were mostly
urologists and only two studies
35,37 were coopera-
tively conducted by urologists and a diagnostic
radiologist or pathologist.
The sensitivity, specificity and percent agree-
ment of prostate-specific antigens as the diag-
nostic parameters of prostate cancer in all 13
studies are listed in Table 2. When the PSA crite-
ria were greater than 4 ng/mL (PSA4), the overall
sensitivity was 91.3% with a range of 73.3% to
100.0%, and the overall specificity was 35.9% with
a range of 13.1% to 88.9%, and each of the values
were scattered widely among the studies. In
addition, the overall percent agreement of PSA4
with the diagnosis was 50.1% with a range of
32.1% to 84.3%. With a PSA > 10 ng/mL (PSA10),
the overall sensitivity was 77.3% with a range of
53.3% to 100.0%, and the overall specificity was
67.5% with a range of 37.7% to 100.0%. In addi-
tion, the overall percent agreement of PSA10 with
the diagnosis was 69.9% with a range of 50.6% to
86.3%.
The data on sensitivity, specificity and percent
agreement for the digital rectal examination and
transrectal ultrasonography for detecting prostate
cancer are shown in Table 3 and Table 4. The
overall sensitivity, specificity and percent agree-
ment (range) for DRE were 68.4% (56.7% to 88.9%),Meta-analysis of PSA, DRE and TRUS
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71.5% (55.9% to 90.4%), and 70.7% (57.8% to 90.2%),
respectively. Also, the overall sensitivity, specifi-
city and percent agreement (range) for TRUS were
73.6% (60.0% to 93.3%), 61.3% (26.5% to 91.7%),
and 64.6% (37.0% to 92.2%), respectively.
In order to check the possibility that the dif-
ferences in the study results may have occurred
by chance, a homogeneity test was performed on
the all diagnostic tests (Table 5). According to the
outcomes of the homogeneity tests for both PSA
criteria (PSA4 and PSA10), these studies were
homogeneous (Q=16.11, p-value>0.05; Q=13.43,
p-value>0.05), so we used the results in a fixed
effect model. Because both the DRE and TRUS
tests proved to be significant and heterogeneous
(Q=50.12, p-value<0.001; Q=49.70, p-value < 0.001),
a fixed effect model was rejected and we then
used the results in a random effect model.
In a quantitative meta-analysis using the Has-
selblad method, the estimate of d ̅for PSA4,
PSA10, DRE and TRUS were 0.8517 [95% confi-
dence interval (CI): 0.6694, 1.0340], 1.0996 (95%
CI: 0.9459, 1.2534), 0.8398 (95% CI: 0.7169, 0.9627),
and 0.8002 (95% CI: 0.6714, 0.9289), respectively.
Among these diagnostic tools, the estimate of d ̅
for PSA10 was the largest. Also, the estimate of
d ̅ for PSA (PSA4 and PSA10) was larger than that
for DRE and TRUS. However, this diagnostic
triad of prostate cancer is judged by the authors
of this study to be noneffective.
Among the 13 studies, the results of patients
tested by this diagnostic triad were done in only
6 studies.
27,28,30-32,36 The outcomes of combination
testing with PSA, DRE, and TRUS for detecting
prostate cancer are shown in Table 6-1 and Table
6-2. If the PSA4 was negative and only the DRE
or the TRUS was positive, the detection rate (DR)
of prostate cancer was only 6 out of 150 patients
(4.0%). Once two tests were positive, even if the
PSA4 was negative, the DR of prostate cancer
increased from 16.8% to 34.3%. If all results of this
diagnostic triad were positive, the DR of prostate
Table 1. General Characteristics of Studies for the Diagnosis of Prostate Cancer in this Meta-Analysis (N=13)
No. of
Ref.
Authors (Year)
Specialty
of author(s)
Sample
size
Diagnosis by pathological results Age (years)
Cancer BPH Others* Mean Range
26 Kang SG (1991) U 51 15 (29.4) 36 (70.6) - - >50
27 Kim TH et al. (1994) U 133 18 (13.5) 110 (82.7) 5 (3.8) 67.9 50-85
28 Park HK et al. (1994) U 93 19 (20.4) 68 (73.1) 6 (6.5) 70.1 50-89
29 Byun HS (1995) U 81 20 (24.7) 61 (75.3) - 69.8 52-87
30 Park SW et al. (1995) U 78 15 (19.2) 60 (76.9) 3 (3.9) 70.3 47-87
31 Choi JH et al. (1996) U 64 11 (17.2) 53 (82.8) - 68.0 40-90
32 Seo WK et al. (1996) U 201 40 (19.9) 155 (77.1) 6 (3.0) 71.0 51-87
33 Kim JH et al. (1998) U 162 26 (16.0) 136 (84.0) - 62.7 50-84
34 Jung JY et al. (1998) U 130 54 (41.5) 76 (58.5) - 66.0 42-86
35 Yoon JH et al. (1998) DR+U 210 53 (25.2) 157 (74.8) - 67.0 41-96
36 Chang HJ et al. (1999) U
215 36 (16.7) 179 (83.3)
§ - 69.2 54-89
TRUS:133 35 (26.3) 98 (73.7)
§ - - -
37 Kim JH et al. (2000) U+P 265 90 (33.9) 169 (63.8) 6 (2.3) 68.6 47-89
38 Jung BC et al. (2002) U 346 119 (34.4) 219 (63.3) 8 (2.3) 66.0 30-93
Total 2,029 516 (25.4) 1,479 (72.9) 34 (1.7) 67.8 30-93
No. of Ref., Number of Reference; U, Urologist; DR, Diagnostic Radiologist; P, Pathologist.
BPH, Benign Prostate Hyperplasia; TRUS, Transrectal Ultrasonography.
*Others include inflammation (chronic prostatitis), tuberculosis, infarct etc.
All patients took prostatectomy.
82 patients were diagnosed by transurethral prostatectomy.
§The number of patients was recalculated by the data according to the evidence of its study.Jae Mann Song, et al.
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cancer jumped further to 68.3%. Also, if the PSA10
was normal and only the DRE or the TRUS was
positive, the DR of prostate cancer was only 14
out of 313 patients (4.5%). Once two of tests were
abnormal, even if the PSA10 was normal, then the
DR of prostate cancer jumped to 18.8-50.0%. If all
three diagnostic tests were abnormal, the DR of
prostate cancer increased further to 76.8%.
DISCUSSION
Because the estimates of d ̅ were not large (not
close to 3.0) in the results of quantitative meta-
analysis, we concluded that prostate-specific anti-
gen testing, digital rectal examination and tran-
srectal ultrasonography for the diagnosis of pros-
tate cancer were not very effective when used
separately. This estimate (d ̅ ) is analogous to the
effect-size described for the continuous-outcome
measures. Thus, this value (0.8-1.1) as the estimate
of d ̅would suggest poor separation or discri-
mination
24 by each of this diagnostic triad for the
detection of prostate cancer. In general, the mea-
sure d ̅ appears to be more consistent across the
studies than is either the sensitivity or specificity,
but if either (normality or equal variances) of the
assumptions is not met, then the effectiveness
Table 2. Outcomes of Prostate Specific Antigen for Diagnosis of Prostate Cancer by the Study (N=13)
Authors (Year) Diagnostic Criteria TP FP FN TN Sn Sp PA
Kang SG (1991)
4 ng/mL (11 4 4 32) 73.3 88.9 84.3
10 ng/mL 8 0 7 36 53.3 100.0 86.3
Kim TH et al. (1994)
4 ng/mL 16 63 2 52 88.9 45.2 51.1
10 ng/mL 15 29 3 86 83.3 74.8 75.9
Park HK et al. (1994)
4 ng/mL 17 47 2 27 89.5 36.5 47.3
10 ng/mL 15 23 4 51 78.9 68.9 71.0
Byun HS (1995)
4 ng/mL 18 53 2 8 90.0 13.1 32.1
10 ng/mL 18 38 2 23 90.0 37.7 50.6
Park SW et al. (1995)
4 ng/mL 15 53 0 10 100.0 15.9 32.1
10 ng/mL 15 29 0 34 100.0 54.0 62.8
Choi JH et al. (1996) 10 ng/mL 10 25 1 28 90.9 52.8 59.4
Seo WK et al. (1996)
4 ng/mL 36 105 4 56 90.0 34.8 45.8
10 ng/mL 32 56 8 105 80.0 65.2 68.2
Kim JH et al. (1998) 4 ng/mL 26 73 0 63 100.0 46.3 54.9
Jung JY et al. (1998)
4 ng/mL 50 61 4 15 92.6 19.7 50.0
10 ng/mL 41 21 13 55 75.9 72.4 73.8
Yoon JH et al. (1998)
4 ng/mL 51 126 2 31 96.2 19.7 39.0
10 ng/mL 43 78 10 79 81.1 50.3 58.1
Chang HJ et al. (1999)
4 ng/mL 33 77 3 102 91.7 57.0 62.8
10 ng/mL 29 28 7 151 80.6 84.4 83.7
Kim JH et al. (2000) 4 ng/mL 74 106 16 69 82.2 39.4 54.0
Jung BC et al. (2002)
4 ng/mL 114 168 5 59 95.8 26.0 50.0
10 ng/mL 83 64 36 163 69.7 71.8 71.1
Pooled results 4 ng/mL 461 936 44 524 91.3 35.9 50.1
10 ng/mL 309 391 91 811 77.3 67.5 69.9
TP, True Positive; FP, False Positive; FN, False Negative; TN, True Negative.
Sn, Sensitivity; Sp, Specificity; PA, Percent Agreement.
All bold numbers were directly calculated in this study using each formula.Meta-analysis of PSA, DRE and TRUS
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measure will not be independent of the cutoff
point.
23 Caution is recommended in using and
interpreting this measure of effectiveness, unlike
the receiver operating characteristic (ROC) curve,
when assumptions are substantially violated (see
Moses et al.).
39
Table 3. Outcomes of Digital Rectal Examination for Diagnosis of Prostate Cancer by the Study (N=13)
Authors Year TP FP FN TN Sn Sp PA
Kang SG 1991 9 5 6 31 60.0 86.1 78.4
Kim TH et al. 1994 16 11 2 104 88.9 90.4 90.2
Park HK et al. 1994 14 17 5 57 73.7 77.0 76.3
Byun HS 1995 17 24 3 37 85.0 60.7 66.7
Park SW et al. 1995 12 13 3 50 80.0 79.4 79.5
Choi JH et al. 1996 7 19 4 34 63.6 64.2 64.1
Seo WK et al. 1996 27 24 13 137 67.5 (85.1) 81.6
Kim JH et al. 1998 20 22 6 114 76.9 83.8 82.7
Jung JY et al. 1998 39 32 15 44 72.2 57.9 63.8
Yoon JH et al. 1998 38 58 15 99 71.7 63.1 65.2
Chang HJ et al. 1999 30 51 6 128 83.3 71.5 73.5
Kim JH et al. 2000 51 56 39 119 56.7 68.0 64.2
Jung BC et al. 2002 73 100 46 127 61.3 55.9 57.8
Pooled results 353 432 163 1,081 68.4 71.5 70.7
TP, True Positive; FP, False Positive; FN, False Negative; TN, True Negative.
Sn, Sensitivity; Sp, Specificity; PA, Percent Agreement.
All bold numbers were directly calculated in this study using each formula.
Table 4. Outcomes of Transrectal Ultrasonography for Diagnosis of Prostate Cancer by the Study (N=13)
Authors Year TP FP FN TN Sn Sp PA
Kang SG 1991 14 3 1 33 93.3 91.7 92.2
Kim TH et al. 1994 15 11 3 104 83.3 90.4 89.5
Park HK et al. 1994 14 20 5 54 73.7 73.0 73.1
Byun HS 1995 16 23 4 38 80.0 62.3 66.7
Park SW et al. 1995 13 23 2 40 86.7 63.5 67.9
Choi JH et al. 1996 9 30 2 23 81.8 43.4 50.0
Seo WK et al. 1996 27 40 13 121 67.5 75.2 73.6
Kim JH et al. 1998 24 100 2 36 92.3 26.5 37.0
Jung JY et al. 1998 34 22 20 54 63.0 71.1 67.7
Yoon JH et al. 1998 47 51 6 106 88.7 67.5 72.9
Chang HJ et al. 1999 (133)* 21 56 14 42 60.0 42.9 47.4
Kim JH et al. 2000 66 99 24 76 73.3 43.4 53.6
Jung BC et al. 2002 79 76 40 151 66.4 66.5 66.5
Pooled results 379 554 136 878 73.6 61.3 64.6
TP, True Positive; FP, False Positive; FN, False Negative; TN, True Negative.
Sn, Sensitivity; Sp, Specificity; PA, Percent Agreement.
All bold numbers were directly calculated in this study using each formula.
*Among the total subjects (215), these patients were taken transrectal ultrasonography.Table 6-2. Outcomes of Combination Testing of PSA10, DRE and TRUS for Detection of Prostate Cancer by the Study (N=5)
Test
Study
PSA10 - + - - + + - +
Total DRE - - + - + - + +
TRUS - - - + - + + +
Kim TH et al. (1994) 0/71 2/26 0/7 0/6 1/3 0/3 3/5 12/12 18/133
Park HK et al. (1994) 3/28 0/20 0/6 0/10 2/4 2/3 1/11 11/11 19/93
Choi JH et al. (1996) 1/12 1/5 0/4 0/8 0/4 2/13 0/5 7/13 11/64
Seo WK et al. (1996) 5/69 2/39 0/9 2/28 6/12 4/13 1/6 20/25 40/201
Chang HJ et al. (1999) 0/10 0/4 2/22 1/23 11/17 4/15 4/21 13/21 35/133
Total 9/ 190
(4.7)
5/ 94
(5.3)
2/ 48
(4.2)
3/ 75
(4.0)
20/ 40
(50.0)
12/ 47
(25.5)
9/ 48
(18.8)
63/ 82
(76.8)
123/ 624
(19.7)
Data: No. of cancer patients in biopsy result/No. of patients tested by diagnostic triad (%).
PSA10, Prostate Specific Antigen (greater than 10 ng/mL)
DRE, Digital Rectal Examination; TRUS, Transrectal Ultrasonography.
-: Negative result (normal) in the diagnostic test, +: Positive result (abnormal) in the diagnostic test.
Jae Mann Song, et al.
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Table 6-1. Outcomes of Combination Testing of PSA4, DRE and TRUS for Detection of Prostate Cancer by the Study (N=5)
Test
Study
PSA4 - + - - + + - +
Total DRE - - + - + - + +
TRUS - - - + - + + +
Kim TH et al. (1994) 0/42 2/55 0/4 0/6 1/6 0/3 3/3 12/14 18/133
Park HK et al. (1994) 2/15 1/33 0/3 0/7 2/7 2/6 0/4 12/18 19/93
Park SW et al. (1995) 0/1 0/31 0/2 0/6 2/8 3/15 0/1 10/14 15/78
Seo WK et al. (1996) 3/42 4/66 0/6 0/8 6/15 6/33 1/3 20/28 40/201
Chang HJ et al. (1999) 0/0 0/14 1/8 0/0 12/31 5/38 2/15 15/27 35/133
Total 5/ 100
(5.0)
7/ 199
(3.5)
1/ 23
(4.3)
0/ 27
(0.0)
23/ 67
(34.3)
16/ 95
(16.8)
6/ 26
(23.1)
69/ 101
(68.3)
127/ 638
(19.9)
Data: No. of cancer patients in biopsy result/No. of patients tested by diagnostic triad (%).
PSA4, Prostate Specific Antigen (greater than 4 ng/mL)
DRE, Digital Rectal Examination; TRUS, Transrectal Ultrasonography.
-: Negative result (normal) in the diagnostic test, +: Positive result (abnormal) in the diagnostic test.
Table 5. Summary of Meta-Analysis Results by Diagnostic Method for Prostate Cancer
Diagnosis
Method
DF Estimate of d ̅ Variance of d ̅
95% Confidence
Interval of d ̅
Q Statistics p value
PSA4 11 0.8517 0.0087 0.6694 1.0340 16.1136 0.1370
PSA10 10 1.0996 0.0062 0.9459 1.2534 13.4319 0.2005
DRE 12 0.8398 0.0039 0.7169 0.9627 50.1208 <0.001
TRUS 12 0.8002 0.0043 0.6714 0.9289 49.7032 <0.001
PSA4, Prostate Specific Antigen (greater than 4 ng/mL)
PSA10, Prostate Specific Antigen (greater than 10 ng/mL)
DRE, Digital Rectal Examination; TRUS, Transrectal Ultrasonography.
DF, Degree of Freedom.Meta-analysis of PSA, DRE and TRUS
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According to the rapid advances in diagnostic
technology, new diagnostic procedures like PSA
and TRUS were introduced to the Korean Medical
Association (KMA) in the early 1980s, and many
Korean studies on this diagnostic triad of PSA,
DRE and TRUS for the diagnosis of prostate can-
cer have been undertaken since the early 1990s.
The widespread application of diagnostic tech-
niques, and especially PSA and systematic bio-
psies, have played an important role in the in-
creased incidence of prostate cancer.
3,40 Also, the
issues concerning clinical practice guidelines
(CPGs) have also established after 1990 by the
KMA,
41 and the Korean Urological Association
began developing the CPGs for prostate cancer a
couple of years ago. Therefore, in this study, we
conducted a meta-analysis of PSA, DRE, and
TRUS for diagnosing prostate cancer among those
subjects with lower urinary symptom, and we
particularly focused on sensitivity and specificity
according to the eligibility of some databases, like
Medline, when searching for Korean articles
published since the mid-1990s.
Because the outcome data used in this study
were based on retrospective observational studies,
there would be considerable variation for the
results of primary studies of this diagnostic triad.
Furthermore, it was proved that 13 studies were
heterogeneous with a statistical significance for
both DRE and TRUS criteria, unlike the PSA cri-
teria (PSA4 and PSA10). This variation may have
been caused by chance alone (the small sample
sizes), but it can also reflect true heterogeneity.
Possible clinical sources of such heterogeneity are
the between-study differences for the type of test
that was used, the selected positivity cutoff point
of each test, the patient selection and clinical
setting, deficiencies in study design (methodolo-
gical heterogeneity), or any combination of these
factors.
42,43 To minimize variations of study
quality in the meta-analysis for the diagnostic
tests, the Cochrane Methods Working Group on
Screening and Diagnostic Tests have suggested
that the comprehensive validity checklist for pri-
mary studies include the study population's re-
cruitment, the patient selection method (selection
bias), the verification method (differential refer-
ence standard bias), the interpretation of tests
method, and the method to avoid residual con-
founding.
44,45 Therefore, this meta-analysis used
only those studies that met the inclusion criteria
(including using biopsy results as a reference
standard and excluding screening tests on general
population
46,47) for quality evaluation. Also,
because the search was restricted to Korean-
language studies, there may be a considerable
(English) language bias. In addition, to eliminate
any multiple publication bias when there were
several articles (including any masters thesis)
written by the same authors, clinical data from the
most recent publication were used.
48
Among the several major outcomes of this
meta-analysis, the most important outcome was
the comparison of PSA, DRE and TRUS as diag-
nostic tests to detect prostate cancer. The overall
sensitivity and overall specificity for PSA4 were
91.3% and 35.9%, respectively; and those for
PSA10 were 77.3% and 67.5%, respectively. Also,
those for DRE were 68.4% and 71.5%, respectively;
and those for TRUS were 73.6% and 61.3%, re-
spectively. If a Korean man with lower urinary
symptoms has abnormal PSA levels or DRE or
TRUS findings, the chances of him having cancer
are about 2 in 5; conversely, when the PSA levels
or findings on DRE or TRUS are normal, the
chance of missing the cancer is about 10%. Also,
the detection rate (50.0%) of combination testing
of PSA10 and DRE were larger than that (44.1%
or 45.0%) of PSA10 or DRE alone. Further, the
detection rate of combination testing of PSA4 or
PSA10 with DRE and TRUS jumped to 68.3% or
76.8%. Thus, when this diagnostic triad was ab-
normal, our result (the probability of prostate
cancer) is same or is larger than that (68%) of the
Haid et al. study.
18 What exactly does all this
mean to the clinician? It means that diagnostic
triad for the detection of prostate cancer in men
with lower urologic symptoms is a useful tool.
Once the PSA is elevated more than 10 ng/mL or
the DRE and TRUS are abnormal, then an
invasive procedure with close follow-up appears
to be necessary.
However, a PSA of greater than 4.0 ng/mL has
limited specificity because such elevations also
occur in men with benign disease (e.g., prostatic
hyperplasia and prostatitis). It is well known that
PSA values for prostate cancer and benign pro-
state hyperplasia have considerable overlap.Jae Mann Song, et al.
Yonsei Med J Vol. 46, No. 3, 2005
Reducing the PSA cutoff point from 10 ng/mL to
4 ng/mL can increase the sensitivity, but doing so
will further reduce the specificity. Also, the DRE
as a time-honored method of diagnosis may show
false negative and positive results.
49 TRUS is not
highly accurate for staging prostate cancer, and it
has an overall reported accuracy of only 58%.
50
The American College of Preventive Medicine
(ACPM),
51 the American Urological Association
(AUA),
52 the Singapore Ministry of Health
(MOH)
,53 the American Cancer Society (ACS),
54
and the U.S. Preventive Services Task Force
(USPSTF)
55 have recently presented their recom-
mendations for screening men for prostate cancer
along with the explicit reasoning behind their
judgment. Among these five groups, the guide-
lines from the Singapore MOH and AUA pro-
vided recommendations for the diagnosis, treat-
ment and management of prostate cancer in addi-
tion to their screening recommendations for this
disease. Men aged 50 or older with a life expec-
tancy of greater than 10 years should be given in-
formation about the potential benefits and harms
of screening for prostate cancer. Although there is
agreement among all the groups on the use of
PSA and DRE as the primary screening tests for
prostate cancer, the AUA, Singapore MOH and
ACS explicitly recommend combining the two
tests to improve accuracy. Further, the use of
TRUS as a screening test for prostate cancer is no
longer considered valid by the ACPM or USPSTF,
and the AUA recommends against it. Similarly,
the Singapore MOH does not address TRUS as a
screening test, but rather, it is considered in com-
bination with biopsy for diagnostic purposes.
56
In conclusion, urologists should take the char-
acteristics of the diagnostic triad (PSA, DRE and
TRUS) and the outcomes of meta-analysis (pooled
sensitivity and specificity, the estimates of d ̅ ) into
consideration. They should use these methods as
a combination rather than separately imple-
menting these methods for the primary diagnosis
of prostate cancer in men with lower urological
symptoms.
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